1. Introduction
===============

Chemotherapy is one of the most important methods in fighting cancer and several members of modified natural alkaloids serve as deserving drugs against tumors. Well-known representatives of vinca alkaloids such as vinblastine, camptothecine, staurosporine and ellipticin \[[@B1-molecules-17-02316],[@B2-molecules-17-02316],[@B3-molecules-17-02316],[@B4-molecules-17-02316]\] are typical examples. Cinchona alkaloids have been proved to be efficient antimalarial \[[@B5-molecules-17-02316]\] and antibacterial drug candidates \[[@B6-molecules-17-02316]\]. It is well-documented that the application of quinine derivatives in the field of cancer detection \[[@B7-molecules-17-02316],[@B8-molecules-17-02316]\] and in chemotherapy \[[@B9-molecules-17-02316],[@B10-molecules-17-02316],[@B11-molecules-17-02316],[@B12-molecules-17-02316],[@B13-molecules-17-02316],[@B14-molecules-17-02316]\] goes far back to the past. Since ferrocene-based molecules as anti-tumor agents are also promising matherials \[[@B15-molecules-17-02316],[@B16-molecules-17-02316],[@B17-molecules-17-02316],[@B18-molecules-17-02316],[@B19-molecules-17-02316],[@B20-molecules-17-02316],[@B21-molecules-17-02316]\] with a wide range of biological activities \[[@B22-molecules-17-02316]\] first we envisaged the synthesis of novel ferrocene-based *mono*- and *bis*-quinines containing amide, urea, thiourea and acylthiourea linkers providing hydrophilic character along with different hydrogen bond profile for the models subjected to *in vitro* assays. This choice of functional groups can also be reasoned by the following facts: (i) a number of aromatic urea derivatives play important role as anticancer agents \[[@B23-molecules-17-02316]\]; (ii) similarly, urea-based prodrugs have been reported as candidates for melanocyte-directed enzyme therapy \[[@B24-molecules-17-02316]\]; (iii) thiourea based molecules have been proved to be effective agents in the treatment of human promyelocytic leukemia \[[@B25-molecules-17-02316]\]; (iv) the antiproliferative activity \[[@B26-molecules-17-02316]\] and citotoxicity \[[@B27-molecules-17-02316]\] of some acyl-thiourea derivatives are worth to be noted and a few patents have also been published in this field \[[@B28-molecules-17-02316],[@B29-molecules-17-02316]\].

The pronounced efficiency of several drugs with C~2~-symmetry \[[@B30-molecules-17-02316],[@B31-molecules-17-02316],[@B32-molecules-17-02316]\] and *bis*-quinolines \[[@B33-molecules-17-02316],[@B34-molecules-17-02316],[@B35-molecules-17-02316]\] encouraged us to construct three ferrocene derivatives containing two quinine units with C~2~-symmetry and a reference benzene 1,3,5-tricarboxamide incorporating three quinine units with C~3~-symmetry. Two further purely organic models with one- and two quinine moieties, respectively, were also prepared as additional references.

2. Results and Discussion
=========================

2.1. Synthesis of the Model Compounds
-------------------------------------

For each synthesis reported in this contribution (*S*)-{\[(2*S*,4*R*,8*R*)-8-ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)}methanamine (**1**) \[[@B36-molecules-17-02316],[@B37-molecules-17-02316]\] was used as common precursor serving as source of quinine moiety. In the presence of dimethylaminopyridine (DMAP) the treatment of **1** with the corresponding acylating agent (fluorocarbonylferrocene, 1,1\'-*bis*-fluorocarbonylferrocene, 1,3,5-*tris*-chlorocarbonylbenzene) in DCM afforded amides **2**, **3** and **8**. In dry THF the additions of **1** on heterocumulene-type reactants (1,1\'-*bis*-isocyanatoferrocene, benzoylisothiocyanate and ferrocene-1,1\'-*bis*-carbonylisothiocyanate) resulted in the formation of urea- and *N*-acylisothiocyanate derivatives **4** and **5**, **6**. The purely organic thiourea model **7** of C~2~-symmetry was obtained by using thiocarbonyl-diimidazole (TCDI) as reagent. Unstable heterocumulenes 1,1\'-bis-isothiocyanato-carbonylferrocene and benzoylisothiocyanate obtained by the reactions of potassium isothiocyanate in acetone at 25 °C with 1,1\'-*bis*-chlorocarbonylferrocene and benzoylchloride, respectively, were used without purification. The low yields of **4**--**6** (2%--10%) may be ascribed to a variety of competitive transformations including acylation- and bridging reactions along with uncontrolled polymerization processes. Their purification required repeated column chromatography and recrystallization until the ^1^H-NMR spectra displayed no major impurities.

![Synthesis of ferrocene-based- and purely organic quinine derivatives.](molecules-17-02316-g001){#molecules-17-02316-f001}

2.2. Theoretical Calculations
-----------------------------

Since the attempts to grow crystals suitable for X-ray analysis have failed so far, the preferred conformations of the new compounds with potential relevance for receptor binding properties were examined by routine DFT calculations \[[@B38-molecules-17-02316]\]. The geometry optimization of the *bis*- and *tris*-cinchona derivatives (**3**--**5**, **7** and **8**) was carried out using the appropriate symmetry constraint (C~n~ n = 2,3). It was found that in each model compound the N-1 atom is situated in the proximity of the hydrogen atom of the NH group directly attached to the cinchona skeleton (calculated distances: 2.1--2.3 Å) to form a five membered chelate ring representing a hydrophilic segment of the molecule. As evidenced by its downfield-shifted ^1^H-NMR signal, this NH group is also incorporated in an additional six-membered chelate ring in the acylthiourea derivatives **5** and **6** considerably decreasing the flexibility of these molecules. In the optimized structures of **2**--**5** the Cp-rings are in the eclipsed position relative to each other and the attached functional groups (amide, urea and acylthiourea) are practically coplanar with them (see Supporting Data for the atomic coordinates).

2.3. Structure Determination
----------------------------

The supposed structures of the new compounds investigated **2**--**8** are consistent with their spectral parameters, so only the following remarks are necessary: the C~2~- and C~3~-symmetric structures of **3**--**5**, **7** and **8**, respectively, are confirmed by the identical spectral data of the two or three chincona residues incorporated in these compounds. In acylthioureas **5** and **6** the presence of the chelate rings gains support from the significantly downfield-shifted ^1^H-NMR signal of the NH group directly bonded to C-9 atom. The relative configuration of the cinchona unit in each compound investigated was evidenced by DNOE measurements revealing *endo* position of H-9 in the proximity of H-5~α~- and H-7~α~, respectively. Accordingly, NOE's were detected between H-6~α~ and the proton of the NH group attached to C-9 atom. Their proximity is also reflected from the significant downfield shift of the H-6~α~ signal relative to that of its germinal partner, H-6~β~ (Δδ = 0.6--0.7 ppm). The relative configuration of C-8 centre gains support from the NOE interactions measured between H-2*~endo~*- and H-8 atoms. On irradiation of the protons on the ethyl group significant enhancements of the intensity of H-7~β~ and H-8 signals were observed indicating the relative configuration of the C-3 atom.

2.4. *In Vitro* Activity of the Compounds on Human Tumor Cell Cultures
----------------------------------------------------------------------

We have determined the cytotoxic and cytostatic activity of the compounds *in vitro* on four human tumor cell lines: HL-60 leukemia, HepG2 hepatoma, MCF-7 breast adenocarcinoma and SH-SY5Y neuroblastoma cell cultures and expressed them as IC~50~ values. Therefore cells were treated with the compounds at 10^−4^ to 10^2^μM concentration range and the viability of the cells was determined by MTT-assay.

The data summarized in [Table 1](#molecules-17-02316-t001){ref-type="table"} show that the precursor amine **1** has no antitumor activity *in vitro* on the tested human cancer cell cultures. Among the investigated ferrocene derivatives **2--5** the diamide **3** proved to be the most active on each type of tumor cells (the IC~50~ values of its cytotoxic- and cytostatic effects fall into the ranges between 0.72--1.70 µM and 0.40--1.00 µM, respectively). It is worth to emphasize that the presence of an additional quinine amide moiety in **3** induces a dramatic enhancement in the *in vitro* antitumor activity compared to that of the analogue *mono*-amide **2**. The outstanding efficiency of **3** can probably be attributed to a cooperation of the two functionalities adopting optimal conformation by practically unrestricted rotation of the two Cp rings.

Significant differences are discernible between the activities of ferrocene-based *bis*-urea **4** and *bis*-acylthiourea **5**. While **4** shows considerable activities on each investigated cell line, compound **5** has only selective cytotoxic and cytostatic effect on the HL-60 cells. The spectacularly decreased activity of **5** may be associated with the intramolecular hydrogen bonds and the increased rigidity of the two acylthiourea units stabilized by their chelate structure.

Among the purely organic models thiourea **7** of C~2~-symmetry exhibited significant cytotoxic and cytostatic effects against each tested cancer cell line, especially on HL-60 and SH-SY5Y cultures (cytotoxic effect: IC~50~ = 1.80 and 0.84 µM, cytostatic activity: 10.20 and 4.20 µM, respectively). Acylthiourea **6** and *tris*-amide **8** with C~3~-symmetry also displayed remarkable activities (with higher IC~50~ values: Between 17.60 and 32.20 µM; 2.30 and 8.90 µM, respectively) without *in vitro* cytotoxic effect on MCF-7 cells. On the other hand, these molecules were slightly cytostatic on the same cell lines after overnight incubation ([Table 1](#molecules-17-02316-t001){ref-type="table"}).

molecules-17-02316-t001_Table 1

###### 

*In vitro* cytotoxicity and cytostatic activity of the cinchona derivatives on human tumor cell cultures.

  ------------ -------------------------------------- -------------- -------------- --------------
               **Cell line**                                                        
               HepG2                                  SH-SY5Y        HL-60          MCF-7
  **Compd.**   **Cytotoxicity (IC~50~^a^ in µM)**                                   
  **1**        \>100                                  \>100          \>100          \> 100
  **2**        33.10 ± 3.04                           29.80 ± 4.24   37.70 ± 3.67   25.32 ± 4.60
  **3**        0.72 ± 0.01                            0.78 ± 0.02    1.70 ± 0.05    0.75 ± 0.02
  **4**        4.24 ± 1.12                            0.82 ± 0.54    0.86 ± 0.02    21.70 ± 3.23
  **5**        \>100                                  \>100          6.70 ± 0.02    \>100
  **6**        17.60 ± 0.25                           21.20 ± 3.24   32.20 ± 4.67   \>100
  **7**        3.34 ± 1.02                            0.84 ± 0.02    1.80 ± 0.56    5.34 ± 1.78
  **8**        8.90 ± 0.23                            1.50 ± 0.02    2.30 ± 0.05    \>100
               **Cytostatic effect (IC~50~ in µM)**                                 
  **1**        \>100                                  \>100          \>100          \> 100
  **2**        65.00 ± 6.70                           80.70 ± 5.78   41.90 ± 1.45   56.00 ± 4.56
  **3**        0.40 ± 0.17                            0.99 ± 0.10    0.76 ± 0.01    1.00 ± 0.34
  **4**        3.40 ± 0.12                            1.30 ± 0.54    0.94 ± 0.02    5.10 ± 0.67
  **5**        \>100                                  \>100          6.50 ± 3.56    21.80 ± 3.18
  **6**        65.60 ± 3.40                           82.90 ± 6.78   \>100          82.90 ± 7.98
  **7**        4.60 ± 0.02                            4.20 ± 2.30    10.20 ± 1.65   3.89 ± 1.18
  **8**        19.60 ± 2.12                           17.20 ± 3.45   4.50 ± 0.01    2.36 ± 0.01
  ------------ -------------------------------------- -------------- -------------- --------------

^a^ The 50% inhibitory concentration (IC~50~) values were determined from the dose-response curves. The curves were defined using Microcal^TM^ Origin1 (version 7.5) software.

3. Experimental
===============

3.1. General
------------

All chemicals were obtained from commercially available sources (Sigma-Aldrich) and--except for THF--used without further purification. THF was purified by distillation from LiAlH~4~ under inert atmosphere. For the *in vitro* assays 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide \[MTT\], RPMI-1640 medium, DMEM medium, fetal calf serum \[FCS\] and nonessential amino acids were also obtained from Sigma-Aldrich. Melting points (uncorrected) were determined with a Boethius microstage. Merck Kieselgel (230--400 mesh, 60 Ǻ) and alumina (Brockmann I grade, approx. 150 mesh, 58 Ǻ, activated neutral). The reactions were monitored using standard TLC technique and were stopped when no more starting compound was detected.

HL-60 human leukemia cells (ATCC: CCL-240) and the adherent HepG2 human hepatoma cells (ATCC: HB-8065) were cultured in RPMI-1640 medium supplemented with 10% FCS (fetal calf serum, Sigma Ltd.), 2 mM l-glutamine, and 160 μg/mL gentamycin. The adherent MCF-7 human breast adenocarcinoma cells (ATCC: HTB-22) and the adherent SH-SY5Y human neuroblastoma cells were maintained in DMEM medium containing 10% FCS, L-glutamine (2 mM), gentamycin (160 μg/mL), 1 mM pyruvate and 1% nonessential amino acids. Cell cultures were maintained at 37 °C in a humidified atmosphere with 5% CO~2~.

The IR spectra were run in KBr disks on a Bruker IFS-55 FT-spectrometer controlled by Opus 3.0 software. Optical rotations were measured with a Zeiss Polamat A polarimeter. The ^1^H- and ^13^C-NMR spectra were recorded in CDCl~3~ or DMSO-d~6~ solution in 5 mm tubes at RT, on a Bruker DRX-500 spectrometer at 500.13 (^1^H) and 125.76 (^13^C) MHz, with the deuterium signal of the solvent as the lock and TMS as internal standard. DEPT spectra were run in a standard manner, using only a *Θ* = 135° pulse to separate the CH/CH~3~ and CH~2~ lines phased "up" and "down", respectively. The 2D-COSY, HMQC and HMBC spectra were obtained by using the standard Bruker pulse programs. The exact mass measurements were performed using a Q-TOF Premier mass spectrometer (Waters Corporation, 34 Maple St, Milford, MA, USA) in positive electrospray mode.

The precursor \[(*S*)-((2*S*,4*R*,8*R*)-8-ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)methanamine (**1**) was prepared according to the method described by Brunner *et al.* \[[@B36-molecules-17-02316]\] and is simply referred to as "amine" in each procedure described below.

3.2.Synthesis of the Novel Quinine Derivatives
----------------------------------------------

### 3.2.1. N*-{(*S*)-\[(2*S*,4*R*,8*R*)-8-Ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)methyl)}ferrocene-carboxamide* (**2**)

The amine (0.70 g, 2.2 mmol), fluorocarbonylferrocene (0.50 g, 2.2 mmol; prepared from ferrocene carboxylic acid according to the method reported by Galow *et al.* \[[@B39-molecules-17-02316]\]) and dimethylaminopyridine (DMAP; 0.26 g, 2.2 mmol) were dissolved in DCM (10 mL). the solution was stirred at RT under argon for 45 min and evaporated to dryness. The residue was subjected to column chromatography on silica \[eluent: DCM/MeOH (30:1)\] followed by recrystallization from dry ether (using 25 mL for 100 mg substance) to obtain the product as light yellow powder (592 mg, 51%). mp. 184--186 °C; \[α\]~D~^26^: −46.4° (EtOH *c*= 0.23 g/100 mL); IR (cm^−1^): 3313, 1635, 1530, 1512, 1242, 1174, 1029, 581, 489; ^1^H-NMR (DMSO-d~6~): 8.74 (d, 1H, *J* = 4.5 Hz, H-2\'); 7.93 (d, 1H, *J* = 9.2 Hz, H-8\'); 7.90 (br s, 1H, N[H]{.ul}); 7.88 (d, *J*= 7.25 Hz, 1H, H-5\'); 7.60 (d, *J*= 4.5 Hz, H-3\'); 7.40 (d, 1H, *J* = 4.5 Hz, H-3\'); 7.38 (dd, 1H, *J* = 9.2 Hz and 2.5 Hz, H-7\'); 5.77 (br \~d, *J*\~9 Hz, 1H, H-9); 4.77 and 4.76 (2 × br s, 2 × 1H, H-2,5, η^5^-C~5~H~4~); 4.27 (br s, 2H, H-3,4, η^5^-C~5~H~4~); 4.03 (s, 5H, η^5^-C~5~[H]{.ul}~5~); 3.95 (s, 3H, OC[H]{.ul}~3~); 3.45 (br qa, *J* = 8.6 Hz, 1H, H-8); 3.23 (br \~t, *J* \~ 12 Hz, 1H, partly overlapped by the HDO signal of the solvent, H-6~α~); 3.12 (dd, *J* = 13.2 Hz and 9.5 Hz, 1H, H-2*~exo~*); 2.75 (ddd, *J* = 12.5 Hz, 11.4 Hz and 4.5 Hz, 1H, H-6~β~); 2.59 (ddd, *J*= 12.5 Hz, 11.2 Hz, 4.5 Hz, 1H, H-5~β~); 2.44 (br d, *J* = 13.2 Hz, 1H, H-2*~endo~*); 1.55 (br \~s, 1H, H-4); 1.53--1.48 (overlapping m's, 2H, H-5~β~, H-7~β~); 1.43 (m, 1H, H-5~α~); 1.35 (m, 1H, H-3); 1.31 (m, 1H, CH~3~-C[H]{.ul}~A~H~B~); 1.23 (m, 1H, CH~3~-CH~A~[H]{.ul}~B~); 0.82 (t, 3H, *J* = 7.2 Hz, CH~3~); 0.68 (dd, *J* = 13.5 Hz and 8.1 Hz, 1H, H-7~α~); ^13^C-NMR (DMSO-d~6~): 169.2 ([C]{.ul}=O); 158.1 (C-6\'); 148.5 (C-2\'); 146.2 (C-4\'); 145.0 (C-8a\'); 132.1 (C-8\'); 129.3 (C-4a\'); 122.0 (C-7\'); 120.9 (C-3\'); 103.9 (C-5\'); 77.0 (C-1, η^5^-C~5~H~4~); 70.8 (two coalesced lines, C-3,4, η^5^-C~5~H~4~); 70.1 (η^5^-[C]{.ul}~5~H~5~); 69.2 and 69.0 (C-2,5, η^5^-C~5~H~4~); 58.5 (C-8); 58.1 (C-2); 56.4 (O[C]{.ul}H~3~); 50.0 (C-9); 41.9 (C-6); 37.8 (C-3); 29.1 (C-5); 27.9 (CH~3~-[C]{.ul}H~2~); 27.0 (C-7); 25.5 (C-4); 12.9 ([C]{.ul}H~3~-CH~2~); HRMS exact mass calculated for C~31~H~36~N~3~O~2~^56^Fe: 538.2157 \[MH\]^+^; found: 538.2162.

### 3.2.2. N*-{(*S*)-\[(2*S*,4*R*,8*R*)-8-Ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)methyl)}ferrocene-1,1\'-bis-carboxamide* (**3**)

The amine (467 mg, 1.4 mmol), 1,1\'-*bis-*fluorocarbonylferrocene (200 mg, 2.9 mmol; prepared from ferrocene dicarboxylic acid \[[@B39-molecules-17-02316]\]) and DMAP (176 mg, 2.9 mmol) were dissolved in DCM (6 mL) and the solution was stirred under argon for 45 min. The residue obtained by the evaporation of the reaction mixture was purified by flash column chromatography on silica using DCM/MeOH (5:1) as eluent followed by recrystallization from Et~2~O to yield the product as brownish yellow powder (134 mg 21%). mp. 137.5--139.5 °C; \[α\]~D~^26^: −62.1° (EtOH *c*= 0.22 g/100 mL); IR (cm^−1^): 3248, 1645, 1623, 1608, 1533, 1509, 1229, 1175, 1030, 485; ^1^H-NMR (DMSO-d~6~): 8.71 (d, 1H, *J* = 4.5 Hz, H-2\'); 8.02 (br s, 1H, N[H]{.ul}); 7.93 (d, 1H, *J* = 9.2 Hz, H-8\'); 7.85 (br s, 1H, H-5\'); 7.63 (d, 1H, *J* = 4.5 Hz, H-3\'); 7.40 (dd, 1H, *J* = 9.2 Hz and 2.5 Hz, H-7\'); 5.72 (br \~d, *J*\~8 Hz, 1H, H-9); 4.64 (br s, 2H, H-2,5, η^5^-C~5~H~4~); 4.53 and 4.50 (2 × br s, 2 × 1H, H-3,4, η^5^-C~5~H~4~); 3.94 (s, 3H, OC[H]{.ul}~3~); 3.57 (br\~t, *J* \~ 8 Hz,, 1H, H-8); 3.38 (m, 1H, H-6~α~); 3.16 (dd, *J* = 12.7 Hz and 7.3 Hz, 1H, H-2*~exo~*); 2.68 (ddd, *J*= 12.5 Hz, 11.2 Hz and 4.7 Hz, 1H, H-6~β~); 2.54 (br d, *J* = 12.7 Hz, 1H, H-2*~endo~*); 1.63--1.59 (overlapping m's, 3H, H-4, H-5~β~, H-7~β~); 1.50-1.46 (overlapping m's, 2H, H-3, H-5~α~); 1.42 (m, 1H, CH~3~-C[H]{.ul}~A~H~B~); 1.35 (m, 1H, CH~3~-CH~A~[H]{.ul}~B~); 0.83 (t, 3H, *J* = 7.2 Hz, CH~3~); 0.74 (dd, *J* = 13.2 Hz and 7.7 Hz, 1H, H-7~α~); ^13^C-NMR (DMSO-d~6~): 169.1 ([C]{.ul}=O); 158.2 (C-6\'); 148.6 (C-2\'); 145.9 (C-4\'); 145.1 (C-8a\'); 132.2 (C-8\'); 128.3 (C-4a\'); 122.2 (C-7\'); 121.0 (C-3\'); 103.8 (C-5\'); 78.0 (C-1, η^5^-C~5~H~4~); 72.4 (two coalesced lines, C-3,4, η^5^-C~5~H~4~); 70.7 (two coalesced lines, C-2,5, η^5^-C~5~H~4~); 58.7 (C-8); 58.0 (C-2); 56.5 (O[C]{.ul}H~3~); 49.7 (C-9); 41.9 (C-6); 37.6 (C-3); 28.8 (C-5); 27.8 (CH~3~-[C]{.ul}H~2~); 27.4 (C-7); 25.9 (C-4); 12.7 ([C]{.ul}H~3~-CH~2~); HRMS exact mass calculated for C~52~H~61~N~6~O~4~^56^Fe: 889.4104 \[MH\]^+^; found: 889.4130.

### 3.2.3. *1,1\'-(Ferrocene-1,1\'-diyl)-bis-{3-\[(*S*)-((2*S*,4*R*,8*R*)-8-ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)methyl)}urea* (**4**)

The amine (7.58 g, 23 mmol) and 1,1\'-diisocyanatoferrocene \[[@B40-molecules-17-02316]\] (2.6 g, 9.7 mmol) were stirred in dry THF at RT under argon overnight. After the evaporation of the reaction mixture the crude product was dissolved in DCM/MeOH (10:1) and the solution was passed through Celite and concentrated in *vacuo*. The residue was column chromatographed on silica with DCM/MeOH (10:1) and crystallized by EtOH (15 mL) to obtain the pure product as yellow powder (358 mg, 2%). mp. 230 °C (dec.); \[α\]~D~^26^: −107.0° (EtOH *c*= 0.02 g/100 mL); IR (cm^−1^): 3277, 3244, \~3100--2100 (diffuse), 1678, 1622, 1584, 1510, 1247, 1083, 1029, 599, 486; ^1^H-NMR (CDCl~3~): 11.20 (br s, 1H, N[H]{.ul}, bonded to η^5^-C~5~H~4~); 8.81 (s, 1H, N[H]{.ul}, bonded to C-9); 8.76 (d, 1H, *J* = 4.5 Hz, H-2\'); 8.03 (d, 1H, *J* = 9.2 Hz, H-8\'); 7.98 (br s, 1H, H-5\'); 7.46 (d, 1H, *J* = 4.5 Hz, H-3\'); 7.40 (dd, 1H, *J* = 9.2 Hz and 2.5 Hz, H-7\'); 5.93 (br \~d, *J* \~ 9 Hz, 1H, H-9); 5.02 and 4.13 (2 × br s, 2 × 1H, H-2,5, η^5^-C~5~H~4~); 4.51 (br qa, *J* = 8.8 Hz, 1H, H-8); 4.10 (s, 3H, OC[H]{.ul}~3~); 4.04 (br \~t, *J*\~13 Hz, 1H, H-6~α~); 3.83 and 3.56 (2 × br s, 2 × 1H, H-3,4, η^5^-C~5~H~4~); 3.74 (dd, *J*= 13.2 Hz and 9.5 Hz, 1H, H-2*~exo~*); 3.24--3.16 (overlapping m's, 2H, H-2*~endo~*, H-6~α~); 2.18 (ddd, *J*= 12.5 Hz, 11.2 H and 4.5 Hz, 1H, H-6~β~); 2.03 (br s, H-4); 1.93--1.87 (m, 4H, H-3, H-5~α~, H-5~β~, H-7~β~); 1.49--1.45 (m, 2H, CH~3~-C[H]{.ul}~2~); 0.94 (t, 3H, *J*= 7.2 Hz, CH~3~); 0.87 (dd, *J* = 13.2 and 8.8 Hz, 1H, H-7~α~); ^13^C-NMR (CDCl~3~): 159.0 (C-6\'); 155.2 ([C]{.ul}=O); 148.0 (C-2\'); 145.4 (C-8a\'); 142.6 (C-4\'); 132.2 (C-8\'); 128.5 (C-4a\'); 122.8 (C-7\'); 119.7 (C-3\'); 102.5 (C-5\'); 99.6 (C-1, η^5^-C~5~H~4~); 64.2 and 62.4 (C-3,4, η^5^-C~5~H~4~); 59.0 (two coalesced lines, C-2,5, η^5^-C~5~H~4~); 64.9 (C-8); 56.7 (C-2); 56.4 (O[C]{.ul}H~3~); 50.0 (C-9); 41.2 (C-6); 35.3 (C-3); 26.9 (CH~3~-[C]{.ul}H~2~); 25.34 (C-7); 25.30 (C-4); 25.2 (C-5); 11.9 ([C]{.ul}H~3~-CH~2~); HRMS exact mass calculated for C~52~H~63~N~8~O~4~^56^Fe: 919.4322 \[MH\]^+^; found: 919.4352.

### 3.2.4. *1,1\'-(Ferrocene-1,1\'-dicarbonyl-diyl)-bis-{3-\[(*S*)-((2*S*,4*R*,8*R*)-8-ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)methyl)}thiourea* (**5**)

1,1\'-*bis-*Isothiocyanatocarbonylferrocene was prepared from 1,1\'-*bis-*chlorocarbonylferrocene (2.18 g, 7 mmol) according to the procedure employing potassium isothiocyanate as reagent and acetone as solvent \[[@B41-molecules-17-02316]\]. This reactive intermediate was used without purification after acetone was removed by distillation and the residue was dissolved in THF. The amine (5.39 g, 17 mmol) and 1,1\'-*bis-*(isothiocyanatocarbonyl)ferrocene dissolved in 100 mL of dry THF were stirred overnight at RT under argon. The reaction mixture was concentrated in *vacuo*. The residue was subjected to column chromatography on silica using DCM/MeOH (15:1) as eluent. The partially purified product was dissolved in EtOH and slowly precipitated by water. The precipitate was filtered off then the chromatography and the recrystallization were repeated in order to get rid of the traces of isothiocyanate reagent to afford the pure product as brick-red powder (120 mg, 2%). mp. 167--169 °C; \[α\]~D~^26^: −128.6° (EtOH *c*= 0.22 g/100 mL); IR (cm^−1^): 3157, 1669, 1621, 1540, 1508, 1226, 1160, 1027, 592, 490; ^1^H-NMR (DMSO-d~6~): 11.62 (br s, 1H, N[H]{.ul} inside the chelate); 10.70 (br s, 1H, N[H]{.ul} outside the chelate); 8.74 (d, 1H, *J* = 4.5 Hz, H-2\'); 7.98 (d, 1H, *J* = 9.2 Hz, H-8\'); 7.83 (br s, 1H, H-5\'); 7.58 (d, 1H, *J* = 4.5 Hz, H-3\'); 7.44 (dd, 1H, *J* = 9.2 Hz and 2.5 Hz, H-7\'); 5.97 (br \~d, *J*\~10 Hz, 1H, H-9); 5.16 and 5.08 (2 × br s, 2H, H-2,5, η^5^-C~5~H~4~); 4.53 and 4.50 (2 × br s, 2 × 1H, H-3,4, η^5^-C~5~H~4~); 3.97 (s, 3H, OC[H]{.ul}~3~); 3.50 (br t, *J*= 10.0 Hz, 1H, H-8); 3.23--3.16 (overlapping m's, 2H, H-2*~exo~* and H-6~α~); 2.76 (ddd, *J* = 12.5 Hz, 11.2 H and 4.5 Hz, 1H, H-6~β~); 2.53 (dd, *J* = 13.8 Hz and 4.9 Hz, 1H, H-2*~endo~*); 1.68 (m, 1H, H-5~β~); 1.60 (br s, 1H, H-4); 1.50 (m, 1H, H-5~α~); 1.44 (m, 1H, H-3); 1.28 (br dd, *J* = 13.3 Hz and 10.0 Hz, 1H, H-7~β~); 1.27--1.22 (overlapping m's, 2H, CH~3~-C[H]{.ul}~2~); 0.95 (dd, *J* = 13.5 Hz and 8.2Hz, 1H, H-7~α~); 0.76 (t, 3H, *J*= 7.2 Hz, CH~3~); ^13^C-NMR (DMSO-d~6~): 180.4 ([C]{.ul}=S); 171.6 ([C]{.ul}=O); 158.2 (C-6\'); 148.5 (C-2\'); 144.5 (C-4\'); 145.3 (C-8a\'); 132.3 (C-8\'); 128.7 (C-4a\'); 122.0 (C-7\'); 121.9 (C-3\'); 104.0 (C-5\'); 75.6 (C-1, η^5^-C~5~H~4~); 74.89 and 74.85 (C-3,4, η^5^-C~5~H~4~); 72.4 and 72.0 (C-2.5, η^5^-C~5~H~4~); 60.4 (C-8); 57.8 (C-2); 56.9 (O[C]{.ul}H~3~); 56.5 (C-9); 42.2 (C-6); 37.6 (C-3); 28.7 (C-5); 27.5 (C-4); 26.1 (CH~3~-[C]{.ul}H~2~); 25.7 (C-7); 12.5 ([C]{.ul}H~3~-CH~2~); HRMS exact mass calculated for C~54~H~63~N~8~O~4~S~2~^56^Fe: 1007.3763 \[MH\]^+^; found: 1007.3776.

### 3.2.5. *1-Benzoyl-3-\[(*S*)-((2*S*,4*R*,8*R*)-8-ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)methyl)thiourea* (**6**)

The amine (3.00 g, 9.2 mmol) and benzoylisothiocyanate (1.51 g, 9.2 mmol) were dissolved in dry THF (100 mL). The reaction mixture was stirred overnight at RT and evaporated to dryness. The residue was purified by flash column chromatography on silica using DCM/MeOH (80:1) as eluent to obtain the product as glassy transparent substance (484 mg, 10%). mp. 92--94 °C; \[α\]~D~^26^: −217.3° (EtOH *c*= 0.31 g/100 mL); IR (cm^−1^): 3162, 1667, 1621, 1542, 1507, 1258, 1147, 1027; ^1^H-NMR (CDCl~3~): 11.50 (br s, 1H, N[H]{.ul} inside the chelate); 11.20 (br s, 1H, N[H]{.ul} outside the chelate); 8.64 (d, 1H, *J* = 4.5 Hz, H-2\'); 7.88 (d, 1H, *J* = 9.2 Hz, H-8\'); 7.84 (d, 2H, *J* = 7.3 Hz, H-2,6, Ph); 7.70 (br s, 1H, H-5\'); 7.54 (t, 1H, *J* = 7.3 Hz, H-4, Ph); 7.51 (d, 1H, *J* = 4.5 Hz, H-3\'); 7.35 (dd, 1H, *J* = 9.2 Hz and 2.5 Hz, H-7\'); 5.78 (br \~d, *J*\~8 Hz 1H, H-9); 3.86 (s, 3H, OC[H]{.ul}~3~); 3.28 (br \~t, *J* \~ 8 Hz, 1H, H-8); 3.10--3.05 (overlapping m's, 2H, H-2*~exo~* and H-6~α~); 2.58 (ddd, *J* = 12.5 Hz,11.2 Hz and 4.5 Hz, 1H, H-6~β~); 2.36 (dd, *J*= 13.8 Hz and 4.9 Hz, 1H, H-2*~endo~*); 1.54 (m, 1H, H-5~β~); 1.47 (m, 1H, H-4); 1.37 (m, 1H, H-5~α~); 1.28 (m, 1H, H-3); 1.15--1.05 (m, 3H, H-7~β~, CH~3~-C[H]{.ul}~2~); 0.79 (dd, *J* = 13.5 Hz and 8.2Hz, 1H, H-7~α~); 0.67 (t, 3H, *J* = 7.2 Hz, CH~3~); ^13^C-NMR (CDCl~3~): 180.4 ([C]{.ul}=S); 169.0 ([C]{.ul}=O); 158. 0 (C-6\'); 148.6 (C-2\'); 145.5 (C-4\'); 145.0 (C-8a\'); 133.9 (C-4, Ph); 133.0 (C-1, Ph); 132.3 (C-8\'); 129.5 (C-2,6, Ph); 129.3 (C-3,5, Ph); 128.7 (C-4a\'); 122.0 (two coalesced lines, C-3\', C-7\'); 103.5 (C-5\'); 60.0 (C-8); 57.7 (C-2); 56.4 (O[C]{.ul}H~3~); 55.7 (C-9); 41.9 (C-6); 37.6 (C-3); 29.0 (C-5); 27.7 (C-4); 26.1 (CH~3~-[C]{.ul}H~2~); 25.7 (C-7); 12.8 ([C]{.ul}H~3~-CH~2~); HRMS exact mass calculated for C~28~H~33~N~4~O~2~S: 489.2324 \[MH\]^+^; found: 489.2323.

### 3.2.6. *1,3-Bis-{(*S*)-\[(2*S*,4*R *8*R*)-8-ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)methyl)}thiourea* (**7**)

The amine (7.58 g, 23 mmol) and thiocarbonyldiimidazole (TCDI; 2.08 g, 12 mmol) were stirred in dry THF (150 mL) under argon. After TCDI was slowly dissolved the solution was evaporated and the residue was subjected to flash column chromatography on silica using DCM/MeOH (15:1) as eluent. The resulted oily substance was crystallized by water-ethanol and thoroughly washed with boiling water to obtain the product as white powder (171 mg, 2%). mp. 137--138 °C; \[α\]~D~^26^: −141.8° (EtOH *c*= 0.21 g/100 mL); IR (cm^−1^): 3265, 1622, 1541, 1509, 1257, 1082, 1031; ^1^H-NMR (DMSO-d~6~): 8.58 (d, 1H, *J* = 4.5 Hz, H-2\'); 7.94 (br s, 1H, N[H]{.ul}); 7.82 (d, 1H, *J* = 9.2 Hz, H-8\'); 7.70 (br s, 1H, H-5\'); 7.29 (dd, 1H, *J* = 9.2 Hz and 2.5 Hz, H-7\'); 7.25 (d, 1H, *J* = 4.5 Hz, H-3\'); 5.12 (br d, *J*= 10.0 Hz,1H, H-9); 3.81 (s, 3H, OC[H]{.ul}~3~); 3.00 (dd, *J* = 12.9 Hz and 10.2 Hz, 1H, H-2*~exo~*); 2.95 (br t, *J* = 10.0 Hz, 1H, H-8); 2.85 (br \~t, *J* \~ 12 Hz, 1H, H-6~α~); 2.35 (br \~t, *J*\~12 Hz 1H, H-6~β~); 2.23 (br d, *J* = 12.9 Hz, 1H, H-2*~endo~*); 1.38 (m, 2H, H-4, H-5~β~); 1.28 (m, 1H, H-3); 1.24 (m, 1H, H-5~α~); 1.10--1.05 (m, 2H, CH~3~-C[H]{.ul}~2~); 0.99 (br dd, *J* = 13.3 Hz and 10.3Hz, 1H, H-7~β~); 0.69 (br d, *J*= 13.5 Hz, 1H, H-7~α~); 0.65 (t, 3H, *J* = 7.2 Hz, CH~3~); ^13^C-NMR (DMSO-d~6~): 183.0 ([C]{.ul}=S); 157.9 (C-6\'); 148.3 (C-2\'); 147.0 (C-4\'); 145.0 (C-8a\'); 132.0 (C-8\'); 128.9 (C-4a\'); 121.9 (C-7\'); 121.4 (C-3\'); 104.1 (C-5\'); 60.5 (C-8); 57.8 (C-2); 57.0 (C-9); 56.5 (O[C]{.ul}H~3~); 41.6 (C-6); 37.7 (C-3); 29.0 (C-5); 27.6 (C-4); 26.2 (CH~3~-[C]{.ul}H~2~); 25.9 (C-7); 12.6 ([C]{.ul}H~3~-CH~2~); HRMS exact mass calculated for C~41~H~53~N~6~O~2~S: 693.3951 \[MH\]^+^; found: 693.3959.

### 3.2.7. N*-{(*S*)-\[(2*S*,4*R*,8*R*)-8-Ethylquinuclidin-2-yl\](6-methoxyquinolin-4-yl)methyl)}benzene-1,3,5-tris-carboxamide* (**8**)

The amine (3.60 g 11 mmol), pyridine (0.89 mL 11 mmol) and DMAP (224 mg 1.8 mmol) were dissolved in dry DCM (100 mL). During vigorous stirring 1,3,5-*tris-*chlorocarbonylbenzene (0.66 mL, 3.7 mmol) was added to the solution in one portion. After stirring for 24 h the solution was poured onto ice. DCM was distilled off at atmospheric pressure. The resulted precipitate was filtered off and dried to yield the product as white powder (3.60 g 87%). mp. 245 °C (dec.); \[α\]~D~^26^: −122.9° (EtOH *c*= 0.26 g/100 mL); IR (cm^−1^): 3305, 1658, 1621, 1508, 1229, 1029, 1029; ^1^H-NMR (CDCl~3~): 8.65 (d, 1H, *J* = 4.5 Hz, H-2\'); 8.48 (s, 1H, H-2,4,6, Ph); 8.01 (d, 1H, *J* = 9.2 Hz, H-8\'); 7.95 (br s, 1H, N[H]{.ul}); 7.67 (br s, 1H, H-5\'); 7.37 (dd, 1H, *J* = 9.2 Hz and 2.5 Hz, H-7\'); 7.33 (d, 1H, *J* = 4.5 Hz, H-3\'); 5.45 (br \~d, *J* \~ 10 Hz, 1H, H-9); 3.94 (s, 3H, OC[H]{.ul}~3~); 3.19 (dd, *J* = 13.9 Hz and 9.6 Hz, 1H, H-2*~exo~*); 3.09--3.04 (overlapping m's, 2H, H-6~α~ and H-8); 2.67 (m, 1H, H-6~β~); 2.38 (dd, *J* = 13.9 Hz and 5.0 Hz, 1H, H-2*~endo~*); 1.64 (br s,1H, H-4); 1.62 (m, 1H, H-5~β~); 1.53 (m, 1H, H-5~α~); 1.43 (m, 1H, H-3); 1.35 (ddd, *J* = 13.3 Hz, 10.3 Hz and 5.0 Hz, 1H, H-7~β~); 1.25 and 1.19 (2 × m, 2 × 1H, CH~3~-C[H]{.ul}~2~); 0.96 (dd, *J* = 13.3 Hz and 6.4 Hz, 1H, H-7~α~); 0.78 (t, 3H, *J*= 7.2 Hz, CH~3~); ^13^C-NMR (CDCl~3~): 165.8 ([C]{.ul}=O); 158.3 (C-6\'); 148.0 (C-2\'); 145.8 (C-8\'); 145.6 (C-4a); 134.7 (C-1,3,5 Ph); 132.3 (C-8\'); 129.4 (C-2,4,6, Ph); 128.6 (C-4a\'); 122.0 (C-7\'); 119.1 (C-3\'); 102.1 (C-5\'); 60.7 (C-8); 56.7 (C-2); 56.0 (O[C]{.ul}H~3~); 51.7 (C-9); 41.4 (C-6); 37.5 (C-3); 29.0 (C-5); 27.7 (CH~3~-[C]{.ul}H~2~); 26.1 (C-4); 25.5 (C-7); 12.3 ([C]{.ul}H~3~-CH~2~); HRMS exact mass calculated for C~69~H~82~N~9~O~6~: 1132.6421 \[MH\]^+^; found: 1132.6388.

3.3. *In Vitro* Cytostatic and Cytotoxic Activity of the Compounds
------------------------------------------------------------------

The cells were grown to confluency and were plated into 96-well plate with initial cell number of 5.0--7.5 × 10^3^ per well. After 24 h incubation at 37 °C, cells were treated with the compounds in 200 μL final volume containing 1.0 v/v% DMSO. Cells were incubated with the compounds at 10^−4^--10^2^ μM concentration range for overnight. Control cells were treated with serum free medium (RPMI-1640 or DMEM) only or with DMSO (c = 1.0 v/v%) at 37 °C for overnight. After incubation the cells were washed twice with serum free (RPMI-1640 or DMEM) medium. To determine the *in vitro* cytostatic effect, cells were cultured for a further 72 h in serum containing medium. To measure the *in vitro* cytotoxicity of the compounds, MTT-assay was carried out immediately after the overnight treatment: The cell viability was determined by the following method using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide \[[@B42-molecules-17-02316],[@B43-molecules-17-02316]\]. The solution of MTT (45 μL, 2 mg/mL) was added to each well which was reduced by the respiratory chain \[[@B42-molecules-17-02316],[@B43-molecules-17-02316]\] and other electron transport systems \[[@B44-molecules-17-02316]\] to form precipitated violet formazan crystals within the cell \[[@B45-molecules-17-02316]\]. The amount of these crystals can be determined by spectrophotometry serving as an estimate for the number of mitochondria and hence the number of living cells in the well \[[@B46-molecules-17-02316]\]. After 4 h of incubation the cells were centrifuged for 5 min (900 g) and supernatant was removed. The obtained formazan crystals were dissolved in 50 μL of DMSO and the optical density (OD) of the samples was measured at λ = 540 and 620 nm, respectively, employing ELISA Reader instrument (iEMS Reader, Labsystems, Finland). OD~620~ values were subtracted from OD~540~ values and the percent of cytostasis or cytotoxicity was calculated using equation "Cytostatic effect/Cytotoxicity (%) = \[1 − (ODtreated/ODcontrol)\] × 100" (where OD~treated~ and OD~control~ correspond to the optical densities of the treated and the control cells, respectively). In each case two independent experiments were carried out with 4--8 parallel measurements. The 50% inhibitory concentration (IC~50~) values were determined from the dose-response curves. The curves were defined using Microcal^TM^ Origin1 (version 7.5) software: cytostasis (%) or cytotoxicty (%) was plotted as a function of concentration, fitted to a sigmoidal curve and, based on this curve, the half maximal inhibitory concentration (IC~50~) value was determined representing the concentration of a compound required for 50% inhibition *in vitro* and expressed in micromoles.

4. Conclusions
==============

Among the novel compounds reported in this contribution the *bis*- and *tris*-quinine derivatives exerted a dose-dependent *in vitro* antitumor activity at micromolar concentrations on the investigated tumor cell cultures. The ferrocene-based *bis*-amide **3** of pronounced activity can be considered as a promising lead structure for the development of a novel class of therapeutical agents. The highly promising results also obtained for a metallocene model containing two ureido functional groups (compound **4**) suggest that 1,1\'-disubstituted ferrocene unit with easily rotating Cp-rings seems to be highly beneficial to the desired activity allowing the molecule to adopt a conformation in which the two cooperating groups are situated in optimal distance from each other. On the other hand, the presence of rigid acylthiourea moiety stabilized by chelate structure dramatically decreases the activity on the investigated cell lines.
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